Glycosylation-modified Dendritic Cell Vaccine Primes the Myeloma-Specific T Cell Response

XIONG Hong,WU Qiu-ye,LIAO Hong-li,ZHAO Qing-jie,HOU Jian
DOI: https://doi.org/10.3969/j.issn.1001-2478.2007.01.012
2010-01-01
Abstract:To investigate the stimulatory effect of the glycosylation-modified dendritic cells vaccine pulsed with tumor-associated carbohydrate antigen(TACA) on the activation of autologous T cells of patients with myeloma,the new TACA N-propionyl polysialic acid(NPrPSA) was firstly rendered to express on myeloma cells with chemical and bio-engineering mehtods for tumor cells,and mononucleated cells from peripheral blood of patients with multiple myeloma(MM) were cultivated in serum-free culture medium containing GM-CSF/IFN-γ and TNF-α to develop dendritic cells(DC),and then these DC were pulsed with tumor cells expressing the new TACA,thus preparing the DC vaccine.After the DC vaccine was co-cultivated with the autologous T cells of patients with MM,the CD4~+CD29~+,CD8~+CD28~+ and CD69~+ T cell were analysed by cytometery.It was demonstrated that there were 6 out of 11 patients in the CD138~-NPr-DC group and no one in 7 patients in the CD138~-NPr-DC group showing an increased expression of CD4CD69(P0.05);while there were 8 out of 11 patients in the CD138 ~(+)NPr-DC group and 1 out of 7 patients in the CD138 ~()NPr-DC group showing an increased expression of CD8CD28.(P0.05) Furthermore,there were also 8 out of 11 patients in CD138~-NPr-DC group and 2 out of 7 patients in the CD138~-NPr-DC group showing an increased expression of CD69(P0.05).These results indicate that the glycosylation-modified DC1 vaccine can activate obviously CD4~(+) and CD8~(+)T cells in comparison with the normal cells,thus providing a foundation for the specific eradiation of myeloma cells.
What problem does this paper attempt to address?